Topical ABT-263 in aged mouse skin: original study and readouts
Topical ABT-263 in aged mouse skin: original study and executable parameters
''Original study'': PMID 39630941 / PMCID PMC11810067, ''Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing'' (Aging, 2024).
Executable parameter table
|~ Dimension |~ ABT-263 skin study |
| Organism | aged mice |
| Age | 24-month-old for treatment cohort; 2-month-old young mice as comparator |
| Tissue | dorsal skin |
| Route | topical application directly to skin |
| Drug | ABT-263 (navitoclax) |
| Dose / window | 5 μM for 5 days |
| Vehicle control | DMSO |
| Primary senescence readouts | p16 and p21 gene expression; SA-β-gal+ cells; p21+ cells |
| Safety / perturbation readouts | transient inflammatory response; macrophage infiltration |
| Transcriptomic readout | bulk RNA-seq |
| Functional readout | accelerated subsequent wound closure after pretreatment |
| Pathways induced | hemostasis, inflammation, cell proliferation, angiogenesis, collagen synthesis, extracellular matrix organization |
Interpretation for comparison
# This is a ''skin-local senolytic preconditioning'' study, not a direct OSK comparison and not a lifespan endpoint study.
# It is still usable as a skin comparator for OSK because it shares tissue, age context, and wound-healing functional readout, while also exposing a distinct safety signature (temporary inflammation/macrophage infiltration).
# For head-to-head framing, the crucial comparison dimensions are ''tissue'', ''age'', ''route'', ''duration'', ''functional challenge'', ''senescence readouts'', and ''safety reads''; route matching matters because topical ABT-263 and local AAV-OSK are both local but mechanistically and pharmacokinetically distinct.